ReviewBritish journal of haematology2009
Pharmacotherapy in sickle cell disease--state of the art and future prospects.
Review in British journal of haematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 43 citations in OpenAlex.
- The Interface of Gene Editing with Regenerative Medicine.Engineering (Beijing, China) · 2025Article
- Development and Characterization of a Model for Inducing Fetal Hemoglobin Production in Cynomolgus Macaques (Comparative medicine · 2018Article
- Sickle cell disease in western Sudan: genetic epidemiology and predictors of knowledge attitude and practices.Tropical medicine & international health : TM & IH · 2016Article
- Hydroxyurea in sickle cell disease: drug review.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2014Review
- The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Biologic complexity in sickle cell disease: implications for developing targeted therapeutics.TheScientificWorldJournal · 2013Review
- Common sense model of illness in youth with type 1 diabetes or sickle cell disease.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2011Article
- The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan.BMC international health and human rights · 2010Article
- The in vivo toxicity of hydroxyurea depends on its direct target catalase.The Journal of biological chemistry · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In the last decade, the care of patients with sickle cell disease (SCD) has undergone important advances with better understanding of disease pathophysiology and improvement in standards of care, especially among paediatric patients. Although many new drugs are currently being investigated and are at different stages of development, the pace of drug discovery and utilization has been slow and suboptimal. Hydroxycarbamide (hydroxyurea) has been investigated and utilized for at least two decades. Hydroxycarbamide's efficacy has been demonstrated, albeit with different levels of evidence, in paediatric and adult populations, and yet clinician and patient acceptance and use have been far from ideal. In this review we discuss the current usage of hydroxycarbamide and its possible future indications in SCD, as well as the use of new compounds that have very different mechanisms of action, which may prove safe and efficacious when used alone or in combination in patients with SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.